Dataset Information

Systems level profiling of arginine starvation in ASS1 negative sarcomas reveals ERK and MYC adaptive metabolic reprogramming of TCA anaplerosis and lipid metabolism

ABSTRACT: submission for the paper "Systems level profiling of arginine starvation in ASS1 negative sarcomas reveals ERK and MYC adaptive metabolic reprogramming of TCA anaplerosis and lipid metabolism"

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Jason Held

PROVIDER: MSV000084785 | MassIVE | Thu Jan 09 19:18:00 GMT 2020

SECONDARY ACCESSION(S): PXD017043

REPOSITORIES: MassIVE

ACCESS DATA

Publications

Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming.

Brashears Caitlyn B CB Barlin Meltem M Ehrhardt William R WR Rathore Richa R Schultze Matthew M Tzeng Shin-Chen SC Van Tine Brian A BA Held Jason M JM

Cell death & disease 20200820 8

Arginine auxotrophy due to the silencing of argininosuccinate synthetase 1 (ASS1) occurs in many carcinomas and in the majority of sarcomas. Arginine deiminase (ADI-PEG20) therapy exploits this metabolic vulnerability by depleting extracellular arginine, causing arginine starvation. ASS1-negative cells develop resistance to ADI-PEG20 through a metabolic adaptation that includes re-expressing ASS1. As arginine-based multiagent therapies are being developed, further characterization of the changes ...[more]

PMID: 32814773

Similar Datasets

Project description:About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We had previously demonstrated that dimerization is essential for ERK extranuclear but not nuclear signaling. Furthermore, by molecular biology approaches, we showed that specifically inhibiting ERK extranuclear component, by impeding ERK dimerization, is sufficient for curtailing tumor progression. Here, we have identified a small molecule inhibitor for ERK dimerization in vitro and in vivo that, without affecting ERK phosphorylation, prevents tumorigenesis driven by Ras-ERK pathway oncogenes, both in cellular and animal models. Importantly, this compound is unaffected by resistance-acquisition processes that hamper “classical” Ras-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two novel concepts in cancer therapy: 1) The blockade of sublocalization-specific sub-signals, rather than total signals, as a means of effectively counteracting oncogenic Ras-ERK signaling. 2) Targeting regulatory protein-protein interactions such as dimerization, rather than catalytic activities, within a signaling route, as an approach for producing effective anti-tumoral agents. Strategies aimed at preventing aberrant flux through this route remain an attractive option for therapeutic intervention in cancer. In this respect, drugs inhibiting the kinase activities of BRaf and MEK have yielded promising results. A375p cells treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours. mRNA from A375p cells was extrated using RNeasy mini kit (Qiagen, Germany) according to the manufacturer's instructions. Cells were previously treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours.

Dataset Information

Systems level profiling of arginine starvation in ASS1 negative sarcomas reveals ERK and MYC adaptive metabolic reprogramming of TCA anaplerosis and lipid metabolism

Publications

Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure